Lidocaine Antibody (602): sc-57900

Lidocaine Antibody (602) is a mouse monoclonal IgG1 antibody that detects Lidocaine in non-species reactive applications by enzyme-linked immunosorbent assay (ELISA). Anti-Lidocaine antibody (602) is available in a non-conjugated form, providing researchers with a versatile tool for studying this widely used amino amide-type local anesthetic and Class Ib antiarrhythmic agent. Lidocaine plays a crucial role in clinical settings due to its ability to block fast sodium channels in the cell membrane, which is essential for altering depolarization in neurons. This mechanism is particularly important as it prevents the transmission of action potentials, leading to its anesthetic effects. In cardiac tissues, Lidocaine reduces automaticity by decreasing the slope of phase 0 depolarization, which is vital for managing arrhythmias without significantly affecting the PR interval, QRS complex, or QT interval. However, caution is warranted, as systemic exposure to high levels of Lidocaine can lead to adverse central nervous system and cardiovascular effects. Additionally, Lidocaine is primarily metabolized by the liver enzyme CYP1A2, which converts approximately 90 percent of it into active metabolites, monoethylglycinexylidide and glycinexylidide, further influencing its pharmacological profile. With a molecular weight of 234.34 g/mol and a half-life of 1.5 to 2 hours, Lidocaine remains a critical agent in both anesthesia and cardiac care, making Lidocaine monoclonal antibody (602) an invaluable resource for researchers exploring its diverse applications.